Streetbeat News

Price Targets

KMPR

Analysts have provided 4 ratings for Kemper (NYSE:KMPR) in the last quarter, with an average 12-month price target of $59.5, a decrease from the previous $64.25. The ratings include 1 bullish and 3 somewhat bullish. Analysts from Piper Sandler and Raymond James have adjusted their price targets, with JMP Securities providing the highest target of $75. Kemper's financial indicators show a negative revenue trend, below-average net margin, ROE, and ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 3:01 pm

FOLD

Amicus Therapeutics (NASDAQ:FOLD) received mixed analyst ratings in the last quarter, with 2 somewhat bullish and 2 indifferent ratings. The average 12-month price target for FOLD is $17.00, with a high of $20.00 and a low of $14.00. This target has increased by 11.48% over the past month. Analysts from Morgan Stanley and JP Morgan have adjusted their price targets and ratings, reflecting their latest views on the company's performance and market conditions. Amicus Therapeutics is a biotech company focused on rare metabolic diseases, showing strong revenue growth and efficient cost management but facing challenges in debt management.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 3:01 pm

KYMR

Kymera Therapeutics (NASDAQ:KYMR) has been evaluated by 4 analysts in the past quarter, with 1 bullish, 1 somewhat bullish, and 2 indifferent ratings. The average price target is now $29.5, down from the previous $60.00, indicating a 50.83% decline. Analysts from Wells Fargo, Morgan Stanley, Piper Sandler, and HC Wainwright & Co. have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Kymera is a biotech company focused on targeted protein degradation to treat diseases. Despite a significant decline in revenue growth and below-average ROA, the company has a strong net margin and ROE, with a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 3:01 pm

EMR

Emerson Electric (NYSE:EMR) received 7 analyst ratings in the last quarter, with an average 12-month price target of $108.43, up from the previous $107.00. Ratings include 1 bullish, 4 somewhat bullish, and 2 indifferent. Analysts from Wells Fargo, UBS, Stephens & Co., RBC Capital, Citigroup, and Keybanc have adjusted their price targets and ratings, reflecting their views on the company's market position, revenue growth, net margin, ROE, ROA, and debt management. Emerson Electric operates in automation equipment and services, with significant interests in AspenTech and a former National Instruments business.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 3:01 pm

AYX

Citigroup analyst Tyler Radke has downgraded Alteryx (NYSE:AYX) from Buy to Neutral and set a price target of $48.25.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:51 pm

PTCT

Morgan Stanley analyst Jeffrey Hung has downgraded PTC Therapeutics (NASDAQ:PTCT) from Equal-Weight to Underweight and set a price target of $28.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:40 pm

PRLD

Morgan Stanley analyst Jeffrey Hung has downgraded Prelude Therapeutics (NASDAQ:PRLD) from Equal-Weight to Underweight and reduced the price target from $10 to $4. This reflects a more bearish outlook on the company's stock by the analyst.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:33 pm

VIGL

Morgan Stanley analyst Jeffrey Hung has downgraded Vigil Neuroscience (NASDAQ:VIGL) from Equal-Weight to Underweight and reduced the price target from $13 to $4.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:31 pm

IRON

Morgan Stanley analyst Jeffrey Hung has downgraded Disc Medicine (NASDAQ: IRON) from Overweight to Equal-Weight while increasing the price target from $56 to $65.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:29 pm

SCSC

Northcoast Research analyst Keith Housum has downgraded ScanSource (NASDAQ:SCSC) from Buy to Neutral and set a price target of $36.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:25 pm